Biopharma · FDA Approvals · Stock
IPSC Century Therapeutics
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is d…
Assets on file: CNTY-813
Catalyst calendar
Dated catalysts for IPSC, including recently decided ones.
Recent first-hand events
Every first-hand event for IPSC, newest first.
IPSCCentury TherapeuticsCentury presents CNTY-813 preclinical data at ADA 2026; IND 4Q 2026
New preclinical data show CNTY-813 maintains glucose control >8 months and evades alloimmune rejection without immunosuppression. Phase 1 manufacturing process is established with consistent quality. IND submission remains on track for 4Q 2026 with first clinical data expected 2H 2027.
Peers by market cap
Companies in the same sector closest to IPSC in market value.
EBSEmergent BioSolutionsMarket cap $413.2M · 3 tracked drugs
NGNENeurogeneMarket cap $413.8M · 1 tracked drug · 1 upcoming catalyst
VNDAVanda PharmaceuticalsMarket cap $400.8M · 2 tracked drugs · 4 upcoming catalysts
RCKTRocket PharmaceuticalsMarket cap $399.4M · 3 tracked drugs · 1 upcoming catalyst
AVIRAtea PharmaceuticalsMarket cap $439.8M · 1 tracked drug · 1 upcoming catalyst
ENTAEnantaMarket cap $384.2M · 1 tracked drug · 1 upcoming catalyst
IRDOpus GeneticsMarket cap $381.3M · 3 tracked drugs · 2 upcoming catalysts
CLYMClimb BioMarket cap $447.6M · 1 tracked drug